NCT04659304View on ClinicalTrials.gov

Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19

PHASE1UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 31, 2021

Primary Completion Date

September 30, 2022

Study Completion Date

December 31, 2022

Conditions
Covid19
Interventions
DRUG

Allocetra-OTS

Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.

Sponsors
All Listed Sponsors
lead

Enlivex Therapeutics Ltd.

INDUSTRY

NCT04659304 - Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19 | Biotech Hunter | Biotech Hunter